Comparison · NCT01490580-e782589a
Atropine Atracurium Sufentanil as Treated Population vs Atropine Propofol as Treated Population: Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Atropine Atracurium Sufentanil as Treated Population vs Atropine Propofol as Treated Population: Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2. Trial comparisons, record NCT01490580-e782589a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01490580-e782589a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.469 | 0.364 | 0.577 | wilson | |
| Risk in group 2 | 0.529 | 0.424 | 0.632 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0603 | -0.207 | 0.0901 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.886 | 0.652 | 1.2 | log | |
| Odds ratio, group 1 over group 2 | 0.786 | 0.427 | 1.45 | log | |
| Number needed to treat, for one fewer participant with the outcome on Atropine Atracurium Sufentanil as Treated Population than on Atropine Propofol as Treated Population | 16.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Atropine Atracurium Sufentanil as Treated Population | n=81~* n=79 Received intervention as randomized~* n=2 Allocated to atropine + propofol but did not receive propofol and received atracurium + sufentanil as open-label drug | 38 | 81 | OG000 |
| Group 2 | Atropine Propofol as Treated Population | n=85~* n=83 Received intervention as randomized~* n=1 Allocated to atropine + atracurium + sufentanil but received propofol as open-label drug~* n=1 Allocated to atropine + propofol but did not receive intervention as randomized, received open-label atropine + propofol | 45 | 85 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2
- Description
Survival without risk of neurodevelopmental delay. Risk of neurodevelopmental delay was defined as no Ages and Stages Questionnaires (ASQ) domain score below threshold (-2 SD) at 2 years of corrected age. The ASQ includes 30 items in 5 neurodevelopmental domains: communication abilities, gross motor skills, fine motor skills, problem solving abilities, and personal-social skills. For each domain, the score obtained by the sum of the items ranges from 0 to 60 and the overall maximum ASQ score is 300 points. For each domain, the score can be categorized using established screening thresholds: an ASQ score \<-2 SD below the mean suggests a risk of neurodevelopmental delay in that domai.
- Time frame
- At 2 years corrected age
- Population
To handle missing data on ASQ scores, we performed multiple imputation with chained equations using the SAS MI procedure. The primary analysis was performed on the imputed dataset in the as treated study groups.
Source ClinicalTrials.gov
Trial
- Title
- Premedication Trial for Tracheal Intubation of the NEOnate
- NCT number
- NCT01490580
- Phases
- PHASE2, PHASE3
- Conditions
- Premedication, Endotracheal Intubation
- Interventions
- atropine+ propofol, atropine + atracurium + sufentanil
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Results first posted
- 2019-09-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01490580?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01490580-e782589a